Prospective evaluation of the safety of compounded bulk material L‐asparaginase in dogs with lymphoma
Authors:
- 17 April 2016
- journal article
- research article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 39 (6) , 572-577
Abstract
Use of compounded L‐asparaginase became routine in veterinary oncology when manufacturing of Elspar®was discontinued in 2012. The objective of this study was to evaluate the safety of compounded L‐asparaginase (CLASP,KRSGlobal Biotechnology, Boca Raton,FL,USA) in comparison with Elspar®(LundbeckLLC, Deerfield,IL,USA). In addition, we documented the response toCLASPin combination with a corticosteroid in this population of dogs with lymphoma. Dogs were prospectively treated with 10 000IU/m2CLASPor Elspar®subcutaneously. Corticosteroids were administered concurrently. Adverse events (AE) were assessed according to the Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events v1.1 (VCOG‐CTCAE). Response was recorded. Seventy‐three dogs received 75 treatments (CLASP,n = 47; Elspar®,n = 28). NoAEwere attributed toCLASP. Grade I andII AEprobably or possibly related to treatment were observed following two Elspar®treatments. The overall response rate to the combination ofCLASPand a corticosteroid was 80% (24%CRand 56%PR). In combination with a steroid, the compounded L‐asparaginase evaluated in this study is safe and demonstrates activity against canine lymphoma. In the face of the discontinuation of Elspar®, veterinarians should seek compounded LASP products that have been tested for activity, purity, and sterility.Keywords
This publication has 12 references indexed in Scilit:
- Acute Pancreatitis in Dogs: Advances in Understanding, Diagnostics, and TreatmentTopics in Companion Animal Medicine, 2012
- Acute hyperammonemia after L‐asparaginase administration in a dogJournal of Veterinary Emergency and Critical Care, 2011
- Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1Veterinary and Comparative Oncology, 2011
- Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus documentVeterinary and Comparative Oncology, 2010
- Combination Chemotherapy with Continuous l -Asparaginase, Lomustine, and Prednisone for Relapsed Canine LymphomaJournal of Veterinary Internal Medicine, 2009
- Evaluation of L-asparaginase: Polyethylene Glycol Conjugate Versus Native L-asparaginase Combined with Chemotherapy: A Randomized Double-blind Study in Canine LymphomaJournal of Veterinary Internal Medicine, 1992
- Effects of single-dose l-asparaginase on coagulation values in healthy dogs and dogs with lymphomaAmerican Journal of Veterinary Research, 1992
- Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphomaEuropean Journal of Cancer, 1990
- Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single-agent glucocorticoid treatmentBlood, 1984
- Crystalline l-Asparaginase from Escherichia coli BJournal of Biological Chemistry, 1970